Nahid Tayebi

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2877445/nahid-tayebi-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

2O	556	10	21
papers	citations	h-index	g-index
21	777 ext. citations	6.4	3.3
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
20	No Evidence That Glucosylsphingosine Is a Biomarker for Parkinsond Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance <i>Movement Disorders</i> , 2022 ,	7	2
19	Next-Generation Sequencing Analysis of : The Challenge of Detecting Complex Recombinant Alleles. <i>Frontiers in Genetics</i> , 2021 , 12, 684067	4.5	2
18	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021 , 53, 294-303	36.3	31
17	Clinical evaluation of sibling pairs with gaucher disease discordant for parkinsonism. <i>Movement Disorders</i> , 2020 , 35, 359-365	7	6
16	The natural history of type 2 Gaucher disease in the 21st century: A retrospective study. <i>Neurology</i> , 2020 , 95, e2119-e2130	6.5	8
15	EEG abnormalities in patients with chronic neuronopathic Gaucher disease: A retrospective review. <i>Molecular Genetics and Metabolism</i> , 2020 , 131, 358-363	3.7	4
14	C-terminal Esynuclein truncations are linked to cysteine cathepsin activity in Parkinsond disease. Journal of Biological Chemistry, 2019 , 294, 9973-9984	5.4	23
13	Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?. <i>Trends in Neurosciences</i> , 2019 , 42, 631-643	13.3	6
12	Variation in cognitive function over time in Gaucher disease type 3. <i>Neurology</i> , 2019 , 93, e2272-e2283	6.5	10
11	ACE phenotyping in Gaucher disease. Molecular Genetics and Metabolism, 2018, 123, 501-510	3.7	16
10	Exploring genetic modifiers of Gaucher disease: The next horizon. <i>Human Mutation</i> , 2018 , 39, 1739-175	14.7	28
9	The role of epigenetics in lysosomal storage disorders: Uncharted territory. <i>Molecular Genetics and Metabolism</i> , 2017 , 122, 10-18	3.7	26
8	Glucocerebrosidase haploinsufficiency in A53T Esynuclein mice impacts disease onset and course. <i>Molecular Genetics and Metabolism</i> , 2017 , 122, 198-208	3.7	18
7	Type 2 Gaucher disease in an infant despite a normal maternal glucocerebrosidase gene. <i>American Journal of Medical Genetics, Part A</i> , 2017 , 173, 3211-3215	2.5	4
6	A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease. <i>DMM Disease Models and Mechanisms</i> , 2016 , 9, 769-78	4.1	14
5	Clinical course and prognosis in patients with Gaucher disease and parkinsonism. <i>Neurology: Genetics</i> , 2016 , 2, e57	3.8	23
4	Lysosomal integral membrane protein-2: a new player in lysosome-related pathology. <i>Molecular Genetics and Metabolism</i> , 2014 , 111, 84-91	3.7	46

LIST OF PUBLICATIONS

3	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. <i>JAMA Neurology</i> , 2013 , 70, 727-35	17.2	285
2	Localization of Non-Factor VIII Sequence Involved in the Factor VIII Gene Inversion in Hemophilia A Dogs <i>Blood</i> , 2007 , 110, 1146-1146	2.2	
1	A novel alteration in metaxin 1, F202L, is associated with N370S in Gaucher disease. <i>Journal of Human Genetics</i> , 2004 , 49, 220-222	4.3	4